40P - Clinical implications of re-biopsy in patients with NSCLC harbouring EGFR mutations with acquired resistance to EGFR tyrosine kinase inhibitors

Date 28 March 2014
Event ELCC 2014
Session Lunch and poster display session
Topics Non-Small-Cell Lung Cancer, Metastatic
Personalised Medicine
Translational Research
Presenter Antonio Passaro
Citation Journal of Thoracic Oncology (2014) 9 (Supplement 9): S7-S52. 10.1097/JTO.0000000000000131
Authors A. Passaro1, B. Gori2, A. Leone3, P. Graziano3, F. de Marinis1
  • 1Division Of Thoracic Oncology, European Institute of Oncology, 20141 - Milan/IT
  • 21st Pneumo-oncological Unit, Azienda Ospedaliera S.Camillo Forlanini, 00100 - Rome/IT
  • 3Pathology Unit, Azienda Ospedaliera S.Camillo Forlanini, 00100 - Rome/IT


Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the gold standard for the treatment of patients with advanced or metastatic NSCLC harbouring EGFR mutations. Since aquired resistance occurs at disease progression (PD), increasing efforts have led to the discovery of counter mutations in EGFR exon 20 and C-MET amplification related to molecular resistance. We evaluated the incidence of these mutations in an Italian cohort of EGFR mutated NSCLC patients who had a progression disease after an oral EGFR TKI treatment.